Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Tools

Jørgensen, Heather G and Allan, Elaine K and Mountford, Joanne C and Richmond, Linda and Harrison, Simon and Elliott, Moira A and Holyoake, Tessa L (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-6. ISSN 0301-472X (https://doi.org/10.1016/j.exphem.2005.05.020)

Full text not available in this repository.Request a copy

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

ORCID iDs

Jørgensen, Heather G, Allan, Elaine K, Mountford, Joanne C, Richmond, Linda, Harrison, Simon, Elliott, Moira A ORCID logoORCID: https://orcid.org/0000-0002-9964-5671 and Holyoake, Tessa L;
CORE (COnnecting REpositories)